When it comes to targeted therapy for cancer, most of the antigens have all been from the same “basket”

Overexpressed proteins.

Mutation-derived neoantigens.

Cancer-testis antigens.

The pipeline of drugs going after them is enormous, and the well is running dry. Most tumor cells don’t have high-quality, tumor-specific targets on their surface.

So a handful of companies have gone looking somewhere else. Not at the genes. At the non-genes.

Roughly 98% of the human genome doesn’t code for classical proteins. It’s historically been called “junk DNA,” or more charitably, the dark genome. Turns out, in cancer cells, that machinery sometimes wakes up and starts producing peptides that get loaded onto HLA and displayed on the tumor cell surface.

Healthy cells don’t do this. Tumors do.

Enara Bio has been building a platform around this for a few years. Their EDAPT discovery engine hunts for these dark antigens. Their EnTiCE platform turns them into bispecific T cell engagers.

This week at AACR, they presented ENA101 in an oral session.

It targets DARKFOX-A3, a peptide-HLA complex derived from an alternative open reading frame of FOXM1 and presented on HLA-A*03:01.

Preclinical data showed low-picomolar potency. Tumor-selective cytotoxicity. Complete tumor regression in vivo at low doses.

Those are strong words and you should hold them loosely until the clinic.

But the reason this matters is that DARKFOX isn’t a patient-specific target. It’s shared across patients with lung, breast, and GI cancers. That solves the big manufacturing headache that’s held back personalized neoantigen approaches.

Boehringer Ingelheim already optioned multiple Enara dark antigens for NSCLC vaccines in January 2024, and Enara closed a $32.5M Series B later that year co-led by Pfizer Ventures and M Ventures.

ENA101 is in IND-enabling studies with clinic entry planned for H2 2026.

If the human data tracks the preclinical, the dark proteome goes from niche academic interest to a very real drug category.